Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.64 (
MPP
)
1,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Drug delivery via the eye, nose, gastrointestinal tract and lung is of great interest as they represent patient-compliant and facile methods to administer drugs. However, for a drug to reach the systemic circulation it must penetrate the "mucus barrier". An understanding of the characteristics of the mucus barrier is therefore important in the design of mucus penetrating drug delivery vehicles e.g. nanoparticles. Here, a range of nanoparticles - silica, aluminium coated silica, poly (lactic-co-glycolic acid) (PLGA) and PEGylated PLGA - each with known but different physicochemical characteristics were examined in the presence of mucin to identify those characteristics that engender nanoparticle/mucin interactions and thus, to define "design rules" for mucus penetrating (nano)particles (
MPP
), at least in terms of the surface characteristics of charge and hydrophilicity. Dynamic light scattering (DLS) and rheology have been used to assess the interaction between such nanoparticles and mucin. It was found that negatively charged and hydrophilic nanoparticles do not exhibit an interaction with mucin whereas positively charged and hydrophobic nanoparticles show a strong interaction. Surface grafted poly (ethylene glycol) (
PEG
) chains significantly reduced this interaction. This study clearly demonstrates that the established colloid science techniques of DLS and rheology are very powerful screening tools to probe nanoparticle/mucin interactions.
...
PMID:Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering. 2598 88
This study applies in situ production of hypochlorous acid (HOCl) to improve the therapeutic efficacy of platinum drugs. The phagocytic enzyme myeloperoxidase (MPO) is coated with two functional polyphenol derivatives (platinum prodrug polyphenols and
PEG
polyphenols) and ferric ion by metal phenolic coordination, which can shield MPO from degradation by other compounds in the blood. Moreover, the platinum prodrug can be reduced to cisplatin in cells and produce hydrogen peroxide (H
2
O
2
). The MPO catalyzes the conversion of H
2
O
2
to HOCl in the intercellular environment. The as-prepared MPO Pt
PEG
nanoparticles (
MPP
NPs) can be employed as a reactive oxygen species cascade bioreaction to enhance platinum drug therapy. The
MPP
NPs show prolonged blood circulation and high tumor accumulation as evidenced by
89
Zr-based positron emission tomography imaging. The
MPP
NPs effectively inhibit tumor growth in vivo. As a first-in-class platform to harness the highly toxic HOCl in nanomedicine for cancer therapy, this strategy may open doors for further development of progressive therapeutic systems.
...
PMID:Hypochlorous Acid Promoted Platinum Drug Chemotherapy by Myeloperoxidase-Encapsulated Therapeutic Metal Phenolic Nanoparticles. 2929 12
Bacterial biofilm-related diseases cause serious hazard to public health and bring great challenge to the traditional antibiotic treatment. Photothermal therapy (PTT) has been recognized as a promising alternative solution. However, the therapeutic efficacy of PTT is often compromised by the collateral damage to normal tissues due to the lack of bacteria-targeting capability. Here, a
Staphylococcus aureus
(
S. aureus
)-targeted PTT nanoagent is prepared based on antibody (anti-protein A IgG), polydopamine (PDA), and
PEG
-SH (thiolated poly (ethylene glycol)) functionalized MoS
2
nanosheets (MoS
2
@PDA-
PEG
/IgG NSs, MPPI NSs). The PDA was used as bio-nano interface to facilitate the covalent conjugation of antibody and
PEG
-SH onto the surface of MoS
2
NSs via facile catechol chemistry. Targeted PTT of MPPI NSs shows excellent inactivation efficiency of larger than 4 log (>99.99%) to
S. aureus
both in biofilms (
in vitro
) and in infected tissues (
in vivo
) without causing damage to normal mammalian cells. By contrast, non-targeted PTT of MoS
2
@PDA-
PEG
NSs (
MPP
NSs) only kills
S. aureus
by <90%
in vitro
and <50%
in vivo
. As a result,
S. aureus
focal infection in mice healed much faster after PTT of MPPI NSs than that of
MPP
NSs. The superiority of targeted PTT may originate from the efficient accumulation and close binding of PTT agents to bacterial cells. Therefore, MPPI NSs with bacteria-targeting capability are promising photothermal agents for effective treatment of
S. aureus
focal infection.
...
PMID:Antibody-Functionalized MoS
2
Nanosheets for Targeted Photothermal Therapy of
Staphylococcus aureus
Focal Infection. 3155 42
